QuantRx Biomedical Corp., a diagnostic company focused on developing and commercializing innovative diagnostic products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent extending its lateral flow testing intellectual property suite. This new patent will add significant protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Together with the patented Q-reader technology, QuantRx is able to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer.

“This milestone event for QuantRx marks the culmination of over a decade of research by our exceptional R&D team,” stated Dr. William Fleming, President of Diagnostics at QuantRx. “RapidSense® with its exceptional low level sensitivity, coupled with our unique device technology, allows QuantRx to capitalize on its knowledge base to create tests that, until now, have been limited to laboratory or simple qualitative testing. QuantRx believes that it will offer products that uniquely meet the healthcare needs described by the new U.S. Administration.”

“Our continually expanding intellectual property suite allows QuantRx to enter untouched markets,” added Mr. Walter Witoshkin, QuantRx’ Chairman and CEO. “We are excited by these recent developments which provide a clear path to bring real innovation to the broad U.S. POC marketplace.”